AMWL: Updated Telehealth Margins And Revenue Trends Will Shape Balanced 2026 Outlook

Analysts have lifted their price target on American Well to $7.50 from $6.25, citing updated assumptions around fair value, discount rate, revenue trends, profit margins, and future P/E multiples reflected in recent Street research.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to the higher US$7.50 price target as better aligning with updated fair value assumptions, suggesting that prior models may have been too conservative on how the business is valued.
The revised target reflects refreshed views on revenue trends, with analysts indicating that current projections support a higher valuation multiple than previously applied.
Improved expectations around profit margins are built into recent models, with analysts seeing scope for more efficient execution to support the updated target.
Assumptions for future P/E multiples in Street research are now set at levels that bullish analysts see as more appropriate for the company’s profile. This feeds directly into the higher target.

Bearish Takeaways

Bearish analysts remain cautious that the uplift to US$7.50 depends on model assumptions around revenue and margins that could prove optimistic if execution falls short.
There is concern that the valuation already embeds a meaningful portion of the thesis, leaving less room for error if growth or profitability trends come in weaker than the Street currently assumes.
Some are wary that reliance on higher future P/E multiples in recent research could expose the stock to pressure if sentiment toward the sector or telehealth valuations softens.
Analysts highlighting the risks point out that the new target is sensitive to discount rate and fair value inputs. Any adjustment to these could quickly change the implied upside.

Valuation Changes

Fair Value: The target fair value has risen from $6.25 to $7.50. This indicates a higher assessed equity value per share in the latest models.
Discount Rate: The discount rate has fallen slightly from 8.36% to 8.02%, which modestly increases the present value of projected cash flows.
Revenue Growth: The forecast revenue decline has moderated, shifting from a 4.44% expected drop to a 1.45% expected drop in updated assumptions.
Net Profit Margin: The projected net profit margin has increased from 5.62% to 6.56%, reflecting a more optimistic view on future profitability levels.
Future P/E: The assumed future P/E multiple has edged down from 11.71x to 11.42x, slightly reducing the valuation attributed to earnings in the outer years.

1 view

Key Takeaways

Integrated AI, expanded service offerings, and deepening relationships with major clients are driving strong recurring revenue growth and positioning for future upselling.
Ongoing cost reductions and a shift to higher-margin software are improving profitability, supporting a credible path toward sustained positive cash flow.
Revenue predictability is challenged by declining visit volumes, volatile contract renewals, reliance on non-recurring revenue, ongoing losses, and heightened competitive and macro risks.

Catalysts

About American Well

An enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The ongoing transition of healthcare systems toward more accessible, technology-enabled care is driving increased adoption of digital platforms; management cited expanding deployments (e.g., Military Health System, Florida Blue), underlining a robust pipeline and positioning Amwell for sustained revenue growth as virtual care becomes mainstream.
The significant integration of AI capabilities across Amwell's platform-including automation, clinical decision support, and data analytics-aligns with rising demand for more efficient, data-driven value-based care, supporting improved gross margins and accelerating the path to profitability.
Deepening relationships and contract extensions with large, long-term clients like the Department of Defense (Military Health System) and Florida Blue not only support predictable recurring revenues but also create a foundation for future expansion and upselling of higher-margin services, boosting both revenue and net margins.
Amwell's focus on expanding its digital health service offerings, along with the platform's capability for rapid deployment of additional programs (such as behavioral health and chronic disease management), increases the company's addressable market and provides upside for both revenue and earnings as clients normalize budgets and add new services.
A concerted effort to streamline operations, reduce operating costs, and shift revenue mix toward higher-margin subscription software is resulting in improved adjusted EBITDA and a credible path to positive operating cash flow by 2026, pointing to long-term net margin and earnings potential.

American Well Earnings and Revenue Growth

American Well Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming American Well's revenue will decrease by 1.4% annually over the next 3 years.
Analysts are not forecasting that American Well will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate American Well's profit margin will increase from -37.0% to the average US Healthcare Services industry of 6.6% in 3 years.
If American Well's profit margin were to converge on the industry average, you could expect earnings to reach $14.9 million (and earnings per share of $0.81) by about May 2029, up from -$87.9 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 11.7x on those 2029 earnings, up from -1.5x today. This future PE is lower than the current PE for the US Healthcare Services industry at 28.5x.
Analysts expect the number of shares outstanding to grow by 3.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The one-year renewal of the Military Health System (DHA) contract (rather than a multi-year agreement) and the exclusion of behavioral health and automated care programs due to Department of Defense budget cuts introduce heightened revenue concentration risk and create uncertainty about the stability and duration of high-margin government contract revenues, which can affect revenue predictability and overall top-line growth.
Sustained decline in total visit volumes (down 22.3% year-over-year for Q2) and significant declines in Amwell Medical Group (AMG) visit revenue (down 20.8% year-over-year), when combined with a flattish outlook post-normalization, suggest longer-term challenges in maintaining user engagement and utilization rates, potentially suppressing revenue per visit and limiting EPS growth.
Heavy reliance on non-recurring subscription software revenue (due to the timing of customer go-lives and initial deployments, especially with the Military Health System) results in top-line volatility and questions around the sustainability and scalability of recurring, high-margin revenue-directly impacting future revenue growth and net margins.
While cost reductions in R&D, sales and marketing, and G&A have favorably improved adjusted EBITDA and delayed cash burn, the business is still operating at a loss and is targeting breakeven only by 2026; continued net losses and negative operating cash flow may necessitate further capital raises, leading to dilution risk for shareholders and ongoing pressure on net income.
Macro uncertainty (regulatory changes, provider and payer budget constraints), increased competitive pressure from both large incumbents and new digital health entrants, and possible pricing pressure from growing market consolidation all threaten Amwell's ability to win, renew, or expand major contracts, which could compress margins and lower EBITDA in the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $7.5 for American Well based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $6.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $227.2 million, earnings will come to $14.9 million, and it would be trading on a PE ratio of 11.7x, assuming you use a discount rate of 8.0%.
Given the current share price of $7.91, the analyst price target of $7.5 is 5.5% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on American Well?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Digital Platforms And AI Will Reshape Future Healthcare